According to the Standards of Medical Care in Diabetes by the American Diabetes Association, the use of sodium glucose cotransporter-2 inhibitors (SGLT2is) is recommended after first-line metformin treatment failure for patients with type 2 diabetes (T2D) and comorbid atherosclerotic cardiovascular diseases (CVDs), heart failure (HF), or chronic kidney disease (CKD) (1). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.